Objectives of Study:
|
Starting from the study of angiogenesis of ischemic brain tissue, using multi-mode CT imaging technology, combined with tongnaoyin, to explore the method of Chinese medicine to promote the establishment of collateral circulation after acute cerebral infarction, which is expected to make a new breakthrough in the clinical treatment of acute cerebral infarction.
|
Exclusion criteria:
|
1.History of cerebral hemorrhage or hemorrhagic cerebrovascular disease (including subarachnoid hemorrhage, cerebral hemorrhage and other intracranial hemorrhage confirmed by head CT / MRI) in the past six months;
2.The MRS score of patients with recurrent cerebral infarction was more than 1 before the onset;
3.It was confirmed by examination that cerebral embolism was caused by detachment of mural thrombus of brain tumor, brain trauma, brain parasitic disease, metabolic disorder, rheumatic heart disease, coronary heart disease and other heart diseases complicated with atrial fibrillation and other patients with unknown reasons;
4.Patients with other diseases affecting limb function, such as lameness, osteoarthritis (active stage), rheumatoid arthritis (active stage), gouty arthritis, etc., may affect neurological or functional examination;
5.Diabetic complications (such as severe diabetic nephropathy leading to renal insufficiency, diabetic peripheral neuropathy affecting motor function evaluator, diabetic ketoacidosis, etc.) and recurrent hypoglycemia patients;
6.The patients with severe malnutrition, severe blood diseases (such as hypoproteinemia, severe anemia, etc.) and severe electrolyte disorder which can not be corrected after treatment;
7.The patients with severe heart and lung diseases and chronic liver and kidney dysfunction had ALT and AST > 1.5 times of the normal upper limit and Renal function impairing creatinine (Cr) > the normal upper limit;
8.Women preparing for pregnancy, pregnancy or lactation;
9.Disabled patients (blindness, deafness, mute, mental retardation, mental retardation, physical disability) stipulated by law;
10.Known to be allergic to the components of the drug and allergic constitution;
11.The researcher thinks that it is not suitable for the patient to participate in this clinical research;
12.Patients who participated in other clinical trials within 3 months.
|